Should enoxaparin be administered to a patient with unstable angina?

Enoxaparin Should Be Administered to Patients with Unstable Angina

Enoxaparin is the preferred anticoagulant over unfractionated heparin (UFH) for patients with unstable angina/NSTEMI, except when severe renal failure (creatinine clearance <30 mL/min) exists or CABG is planned within 24 hours. 1, 2

Evidence Supporting Enoxaparin Use

The superiority of enoxaparin over UFH is established by two landmark trials that demonstrated significant reductions in death, myocardial infarction, and recurrent angina:

• ESSENCE trial (n=3,171): Enoxaparin produced a 17% relative risk reduction in the composite endpoint of death, MI, or recurrent angina at 14 days (P=0.019) and 15% reduction at 30 days (P=0.016) compared to UFH 1
• TIMI-11B trial (n=3,910): Enoxaparin achieved an 18% relative risk reduction at 14 days (P=0.029) and 12% reduction at 43 days (P=0.048) 1
• Meta-analysis of these trials showed enoxaparin produced a 20% relative reduction in death and MI during the first 7-14 days of treatment 1

Dosing Regimen

Standard dosing: 1 mg/kg (100 anti-factor Xa units) subcutaneously every 12 hours for 2-8 days during the acute phase 1, 2

Critical dosing adjustments:

• Severe renal impairment (CrCl <30 mL/min): Reduce dose to 64% of standard (approximately 1 mg/kg once daily instead of twice daily) 3, 4
• Age ≥75 years: Consider 0.75 mg/kg subcutaneously every 12 hours without IV bolus 2

Practical Advantages Over UFH

Enoxaparin offers several operational benefits that make it superior in real-world practice:

• No monitoring required: Unlike UFH, which requires aPTT monitoring and frequent dose adjustments, enoxaparin provides predictable anticoagulation without laboratory monitoring 1, 2
• Subcutaneous administration: Easier to administer than continuous IV infusion 1
• Lower risk of heparin-induced thrombocytopenia: Enoxaparin stimulates platelets less than UFH 1

Safety Profile

Bleeding rates are comparable to UFH for major bleeding but higher for minor bleeding:

• Major bleeding: 6.5% with enoxaparin vs 7.0% with UFH (not significantly different) 1
• Minor bleeding: 11.9% with enoxaparin vs 7.2% with UFH (P<0.001), primarily due to bruising at injection sites 1

Monitor daily: Hemoglobin and platelet counts should be checked daily, as severe thrombocytopenia (<50,000/mL) occurs in 0.5% of patients 2

Duration of Therapy

For medically managed patients: Continue enoxaparin for the duration of hospitalization, up to 8 days maximum 2, 4

Important caveat: Extended therapy beyond the acute phase (>14 days) has NOT been shown to provide additional benefit. The FRISC-II trial demonstrated no significant difference in death/MI at 3 months with prolonged dalteparin (6.7% vs 8.0%, P=0.17) but significantly increased bleeding 1

Contraindications and When to Use UFH Instead

Switch to UFH in these specific scenarios:

1. CABG planned within 24 hours: UFH's anticoagulant effect can be rapidly reversed, whereas enoxaparin has a longer half-life that complicates perioperative management 1, 4
2. Severe renal failure (CrCl <30 mL/min): Either use reduced-dose enoxaparin (1 mg/kg once daily) or switch to UFH 4, 3

Combination with Glycoprotein IIb/IIIa Inhibitors

Enoxaparin can be safely combined with GP IIb/IIIa inhibitors without excess bleeding risk:

• ACUTE II trial: Demonstrated similar major and minor bleeding rates when enoxaparin was combined with tirofiban, with a trend toward fewer adverse events compared to UFH plus tirofiban 1
• This combination is appropriate for high-risk patients undergoing early invasive strategy 1

Management During Cardiac Catheterization

If catheterization occurs within 8 hours of last enoxaparin dose: Proceed directly to PCI without additional anticoagulation, as anti-Xa activity remains therapeutic (>0.5 IU/mL in 97.6% of patients) 5

If >8 hours since last dose: Consider supplemental UFH according to usual PCI protocols 1

Common Pitfall to Avoid

Do not extend enoxaparin therapy beyond hospital discharge or 8 days in the outpatient setting for unstable angina. Multiple trials (FRISC, FRIC, FRAXIS, FRISC-II) failed to demonstrate benefit of prolonged LMWH administration beyond the acute phase, while bleeding risk increased significantly 1